Novo Nordisk Abandons Triple-Hormone Obesity Drug as Eli Lilly Advances

Safety Concerns Force Novo Nordisk to Drop Promising Obesity Treatment While Rival Eli Lilly Pushes Forward with Similar Drug

Key Facts

• Global obesity drug market spending reached $30 billion in 2024, up tenfold since 2020
• Novo Nordisk achieved $41 billion in sales for 2024, a 26% year-over-year increase
• Novo shelved a promising triple-hormone obesity treatment due to safety concerns, while competitor Eli Lilly advanced similar therapy

Introduction

A pivotal decision by Novo Nordisk to abandon a groundbreaking triple-hormone obesity treatment in the late 2010s may have cost the Danish pharmaceutical giant its market leadership position. The company’s cautious approach to drug development, while rooted in safety concerns, has allowed competitor Eli Lilly to gain significant ground in what has become a $100 billion market opportunity.

Key Developments

Novo Nordisk initially developed a weekly obesity treatment targeting three hormones simultaneously, demonstrating notable weight loss results in early trials. However, concerns about side effects, including elevated blood sugar and heart rate, led the company to shelve the project. Instead, Novo focused on developing semaglutide, now marketed as Wegovy.

Meanwhile, Eli Lilly seized the opportunity to develop its own triple agonist, retatrutide, which has advanced to late-stage testing. The Indianapolis-based company’s aggressive development approach has positioned it as a strong challenger in the obesity drug market.

Market Impact

The obesity drug market has experienced extraordinary growth, with global spending on anti-obesity medications surging tenfold since 2020. Novo Nordisk’s financial performance reflects this boom, with 2024 sales reaching $41 billion. However, the company’s reduced 2025 outlook has raised investor concerns about its competitive position.

Novo has responded to market pressures by implementing significant price cuts, including a 50% reduction for Wegovy on its NovoCare platform. The company is also pursuing approval for a high-dose oral semaglutide, which could become the first oral GLP-1 obesity treatment.

Strategic Insights

Novo Nordisk’s strategy has centered on expanding indications for existing drugs like Ozempic and Wegovy while scaling up manufacturing capacity. The company’s next-generation obesity drug, CagriSema, showed a 15.7% weight reduction in trials, though this fell short of investor expectations for 25% reduction.

Expert Opinions and Data

Richard DiMarchi, a chemist who led the triple agonist development, expressed frustration with Novo’s approach: “I just never felt there was a conviction within Novo to fight through the obstacles.” This sentiment reflects a broader industry perception of Novo’s risk-averse culture.

Market analysts note that 2025 represents a transition year for the obesity drug market, with increased competition, price pressures, and new market entrants reshaping the competitive landscape. The approach of 2026 brings additional challenges as semaglutide patents expire in some regions and new treatments enter the market.

Conclusion

Novo Nordisk’s conservative approach to drug development, while prioritizing safety, has impacted its competitive position in the rapidly evolving obesity drug market. The company’s early lead has narrowed as competitors, particularly Eli Lilly, have advanced more aggressive development strategies. The market’s transformation from explosive growth to intense competition marks a critical juncture for all players in the obesity drug sector.